FRANCISCO JAVIER
SALMERÓN ESCOBAR
Investigador en el periodo 2002-2020
Hospital Universitario Puerta de Hierro
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Puerta de Hierro (20)
2022
-
Non-pharmacologic direct cost of a simplified strategy with glecaprevir/pibrentasvir for 8 weeks in naïve non-cirrhotic patients with hepatitis C implemented in clinical practice. The Just SIMPLE Study
Gastroenterologia y Hepatologia, Vol. 45, Núm. 5, pp. 342-349
2021
-
Comprehensive analysis and insights gained from long-term experience of the Spanish DILI Registry
Journal of Hepatology, Vol. 75, Núm. 1, pp. 86-97
-
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects
Liver International, Vol. 41, Núm. 9, pp. 2076-2086
2020
-
Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
Antiviral Research, Vol. 174
-
Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis
Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5
-
Erratum to: “Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH (J Hepatol 2020; 73: 17–25) (Journal of Hepatology (2020) 73(1) (17–25), (S0168827820301276), (10.1016/j.jhep.2020.02.028))
Journal of Hepatology
-
Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH
Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25
2019
-
Alcohol-related liver disease. Clinical practice guidelines. Consensus document sponsored by AEEH
Gastroenterologia y Hepatologia, Vol. 42, Núm. 10, pp. 657-676
-
Effectiveness and safety of elbasvir/grazoprevir therapy in patients with chronic HCV infection: Results from the Spanish HEPA-C real-world cohort
Journal of Viral Hepatitis, Vol. 26, Núm. 1, pp. 55-64
-
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort
Liver International, Vol. 39, Núm. 1, pp. 90-97
-
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain
PLoS ONE, Vol. 14, Núm. 11
2018
-
Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
Gastroenterologia y Hepatologia, Vol. 41, Núm. 5, pp. 328-349
-
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C
Journal of Hepatology, Vol. 68, Núm. 5, pp. 940-948
2017
-
Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort
Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311
-
Tenofovir vs lamivudine plus adefovir in chronic hepatitis B: TENOSIMP-B study
World Journal of Gastroenterology, Vol. 23, Núm. 41, pp. 7459-7469
-
Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: Analysis of data from the Hepa-C registry
Hepatology, Vol. 65, Núm. 6, pp. 1810-1822
2015
-
Fine-mapping butyrophilin family genes revealed several polymorphisms influencing viral genotype selection in hepatitis C infection
Genes and Immunity, Vol. 16, Núm. 5, pp. 297-300
2009
-
Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin
Hepatology, Vol. 50, Núm. 6, pp. 1702-1708
2006
-
Cost-effectiveness analysis of lamivudine and adefovir dipivoxil in the treatment of patients with HBeAg-negative chronic hepatitis B
Alimentary Pharmacology and Therapeutics, Vol. 23, Núm. 3, pp. 409-419
2003
-
Comités éticos de investigación clínica y «dictamen único» de los ensayos clínicos multicéntricos
Medicina Clinica, Vol. 120, Núm. 5, pp. 180-188